Evidence map›Paper›PMID 39812845›Full record

ArticleJournal of neurology2025

Clinical and imaging spectrum of non-congenital dominant ACTN2 myopathy.

Pablo Iruzubieta, José Verdú-Díaz, Ana Töpf, Leonela Luce, Kristl G Claeys, Willem De Ridder, Lidia González-Quereda, Carlos Pablo de Fuenmayor-Fernández de la Hoz, Juan José Poza, Miren Zulaica and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Pablo Iruzubieta *Department of Neurology and Neurosciences, Donostia University Hospital, Biogipuzkoa Health Research Institute, Donostia-San Sebastián, Spain.
José Verdú-Díaz *John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle Hospitals NHS Foundation Trust, Newcastle University, Newcastle Upon Tyne, UK.
Ana Töpf *John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle Hospitals NHS Foundation Trust, Newcastle University, Newcastle Upon Tyne, UK.
Leonela LuceJohn Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle Hospitals NHS Foundation Trust, Newcastle University, Newcastle Upon Tyne, UK.
Kristl G ClaeysDepartment of Neurology, University Hospitals Leuven, Louvain, Belgium.
Willem De RidderTranslational Neurosciences and Peripheral Neuropathy Group, University of Antwerp, Antwerp, Belgium.
Lidia González-QueredaGenetics Department, Institut d'InvestigacióBiomèdica Sant Pau (IIB SANT PAU), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Carlos Pablo de Fuenmayor-Fernández de la HozNeuromuscular Disorders Unit, Department of Neurology, Hospital Universitario 12 de Octubre, Avenida de Córdoba Sin Número, 28041, Madrid, Spain.
Juan José PozaDepartment of Neurology and Neurosciences, Donostia University Hospital, Biogipuzkoa Health Research Institute, Donostia-San Sebastián, Spain.
Miren ZulaicaDepartment of Neurology and Neurosciences, Donostia University Hospital, Biogipuzkoa Health Research Institute, Donostia-San Sebastián, Spain.
Peter de JongheTranslational Neurosciences and Peripheral Neuropathy Group, University of Antwerp, Antwerp, Belgium.
Jennifer DuffJohn Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle Hospitals NHS Foundation Trust, Newcastle University, Newcastle Upon Tyne, UK.
Magdalena MroczekJohn Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle Hospitals NHS Foundation Trust, Newcastle University, Newcastle Upon Tyne, UK.
Paloma Martín-JiménezNeuromuscular Disorders Unit, Department of Neurology, Hospital Universitario 12 de Octubre, Avenida de Córdoba Sin Número, 28041, Madrid, Spain.
Aurelio Hernández-LaínNeuromuscular Disorders Unit, Department of Pathology (Neuropathology), 12 de Octubre University Hospital, Madrid, Spain.
Cristina Domínguez-GonzálezCenter for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Universitat Autonoma de Barcelona (UAB), Madrid, Spain.
Jonathan BaetsTranslational Neurosciences and Peripheral Neuropathy Group, University of Antwerp, Antwerp, Belgium.
Pia GallanoGenetics Department, Institut d'InvestigacióBiomèdica Sant Pau (IIB SANT PAU), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Jordi Díaz-ManeraJohn Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle Hospitals NHS Foundation Trust, Newcastle University, Newcastle Upon Tyne, UK.
Volker StraubJohn Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle Hospitals NHS Foundation Trust, Newcastle University, Newcastle Upon Tyne, UK.
Adolfo López de MunainDepartment of Neurology and Neurosciences, Donostia University Hospital, Biogipuzkoa Health Research Institute, Donostia-San Sebastián, Spain. adolfo.lopezdemunainarregui@osakidetza.eus.
Roberto Fernandez-TorronDepartment of Neurology and Neurosciences, Donostia University Hospital, Biogipuzkoa Health Research Institute, Donostia-San Sebastián, Spain. roberto.fernandeztorron@osakidetza.eus.ORCID http://orcid.org/0000-0002-2202-8165

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlpha-actinin-2, a protein with high expression in cardiac and skeletal muscle, is located in the Z-disc and plays a key role in sarcomere stability. Mutations in ACTN2 have been associated with both hypertrophic and dilated cardiomyopathy and, more recently, with skeletal myopathy.

methodsGenetic, clinical, and muscle imaging data were collected from 37 patients with an autosomal dominant ACTN2 myopathy belonging to 11 families from Spain and Belgium. Haplotypes were studied to confirm a common ancestry for the two most common recurrent variants identified in this study. A trained machine learning model was used to compare muscle MRI scans in ACTN2 myopathy with other neuromuscular diseases to identify a specific pattern of muscle involvement.

resultsThe clinical phenotype ranged from asymptomatic to limb-girdle weakness and facial involvement and was depending on genotype. Cardiac and respiratory involvement were not common. Belgian families carrying the p.Ile134Asn variant and Basque-Spanish families carrying the p.Cys487Arg variant each showed unique haplotypes supporting respective common ancestry. Available muscle biopsies showed non-specific changes. In muscle imaging, the most affected muscles were the glutei minor, glutei medius, hamstrings, tibialis anterior, and soleus. A machine learning model showed that the most differentiating features in dominant ACTN2 myopathy were the involvement of the tibialis anterior and gluteus medius muscles and preservation of the quadratus femoris, gastrocnemius lateralis, and tensor fasciae latae muscles.

conclusionWe provide new insights into genetic, clinical, and muscle imaging characteristics of non-congenital dominant ACTN2 myopathy, broadening the phenotypic spectrum of muscle disorders caused by ACTN2 variants.

Indexed as

ActininMuscle, SkeletalMuscular DiseasesAdolescentAdultAgedBelgiumFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedMutationPedigreePhenotypeSpainActininACTN2 protein, humanACTN2Alpha-actininGeneticsMachine learningMyopathy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.